Stocks Health care NTLA
NASDAQ · Health careIntellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. brought in $52.9M of revenue over the twelve months to September 30, 2026, down 8.1% from a year earlier. It posted a net loss of $426.1M. In fiscal 2025 capital spending exceeded operating cash flow by $395.9M. At September 30, 2026 it held $156.1M in cash against $73.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Intellia Therapeutics, Inc.
- Net worth
- Intellia Therapeutics, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $613.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $67.7M (+16.9% year on year), with a net loss of $412.7M. Over the 12 months to September 30, 2026: revenue $52.9M, net loss $426.1M.
- Cash flow
- In fiscal 2025 operations used $394.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Intellia Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Intellia Therapeutics, Inc. does
Intellia Therapeutics, Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker NTLA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $67.7M | -$412.7M | -$3.81 | -$395.9M |
| 2024 | $57.9M | -$519M | -$5.25 | -$354.7M |
| 2023 | $36.3M | -$481.2M | -$5.42 | -$408.1M |
| 2022 | $52.1M | -$474.2M | -$6.16 | -$346.8M |
| 2021 | $33.1M | -$267.9M | -$3.78 | -$237.8M |
| 2020 | $58M | -$134.2M | -$2.40 | -$53.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NTLA ranks in Health care
Latest SEC filings
What Intellia Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 48% to $7.2M versus the same quarter last year; diluted EPS -$0.91 versus -$0.92.
- November 5, 2026
- September 8, 2026
- September 4, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 46% to $7.7M versus the same quarter last year; diluted EPS -$0.80 versus -$0.98.
- August 6, 2026
- June 15, 2026
- June 10, 2026
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 9.5% to $15M versus the same quarter last year; diluted EPS -$0.81 versus -$1.10.
Insider trades
What the people running Intellia Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $417.9K worth of shares in the last 90 days and bought none on the open market. Most of the selling (94%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Leonard John MPresident and CEO, Director | Soldpre-planned (10b5-1) | 9,000 | $107.9K |
| October 26, 2026 | Marantz Jing L.EVP, Chief Medical Officer | Received as pay | 199,822 | - |
| October 2, 2026 | Dube Michael PVP, Chief Accounting Officer | Sold | 1,864 | $23.2K |
| August 21, 2026 | Leonard John MPresident and CEO, Director | Soldpre-planned (10b5-1) | 2,785 | $36.2K |
| August 20, 2026 | Leonard John MPresident and CEO, Director | Soldpre-planned (10b5-1) | 19,890 | $250.6K |
| July 22, 2026 | Dulac Edward J IIIEVP, Chief Financial Officer | Sold | 8,111 | $91.2K |
| July 2, 2026 | Dulac Edward J IIIEVP, Chief Financial Officer | Soldpre-planned (10b5-1) | 4,677 | $84.2K |
| July 1, 2026 | Dube Michael PVP, Chief Accounting Officer | Sold | 2,641 | $44.3K |
Who owns NTLA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ARK Investment Management LLC13G, passive with 1 related filers | 12.27% | February 3, 2026 |
| Vanguard Portfolio Management13G, passive | 5.3% | April 29, 2026 |
| Vanguard Capital Management13G, passive | 5.03% | April 30, 2026 |
Largest institutional holders
Insiders
15 insiders reported holding 2,610,014 shares in total, about $29.2M at the last price.
| Holder | Shares |
|---|---|
| Leonard John MPresident and CEO, Director | 1,138,064 |
| Cohen Fred EDirector | 216,653 |
| Marantz Jing L.EVP, Chief Medical Officer | 199,822 |
| Basta JamesEVP, General Counsel | 156,794 |
| Dulac Edward J IIIEVP, Chief Financial Officer | 148,175 |
| Chase William JDirector | 143,893 |
| Schultes Birgit CEVP, Chief Scientific Officer | 137,733 |
| Lebwohl DavidEVP, Chief Medical Officer | 131,192 |
| Clark ElianaEVP, Chief Technical Officer | 93,864 |
| Dube Michael PVP, Chief Accounting Officer | 65,022 |
Questions about NTLA
What does Intellia Therapeutics, Inc. do?
Intellia Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as NTLA. Its shares trade on NASDAQ under the ticker NTLA.
What is Intellia Therapeutics, Inc.'s net worth?
Intellia Therapeutics, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $613.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Intellia Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $426.1M on revenue of $52.9M.
How much revenue does Intellia Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Intellia Therapeutics, Inc. reported revenue of $52.9M. That is 8.1% less than a year earlier.
When did Intellia Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Intellia Therapeutics, Inc.'s next earnings report?
Intellia Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NTLA with
Follow NTLA
Get an email when Intellia Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Intellia Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.